A journal is retracting a paper linking radio waves from cell phone towers to pain in amputees, despite objections from the authors.
“Anthropogenic Radio-Frequency Electromagnetic Fields Elicit Neuropathic Pain in an Amputation Model,” originally published Jan. 16, 2016 in PLOS ONE, suggested that rats with injured nerves experienced pain when exposed to the type of electromagnetic radiation emitted by cell phone network towers. A press release issued by the University of Texas at Dallas (UT-Dallas) — where the corresponding author Mario Romero-Ortega and two co-first authors are based — said that this phenomenon has been reported anecdotally by people missing limbs.
But the study, especially its methodology, met with immediate criticism in the article’s comment section. PLOS ONEnoted in March 2016 that the authors had contacted the journal regarding an error in some of the exposure levels reported in the study, which journal staff were “looking into.” In December 2016, the journal told the authors it was going to retract the paper. Now, more than one year later, it finally has.
The Swedish government has terminated a four-year grant to a researcher at Uppsala University recently found guilty of misconduct — and, in a first, has also banned him from applying for grants for another two years.
A representative of the Swedish Research Council told us that it is “very rare” for the body to rescind a grant — and it has never simultaneously rescinded a grant and temporarily banned the researcher from applying for funding.
Too many papers cite retracted research — even after it’s been retracted. It’s a problem. It can be especially a problem in clinical fields, where patient care is at stake. Recently, Richard Gray at La Trobe University in Australia and his colleagues examined the scope of the problem in the nursing field, noting how many systematic reviews included findings from retracted clinical trials. We spoke with Gray about their findings, published in the International Journal of Nursing Studies — and what they might mean for the safety of patients.
Retraction Watch: Retractions are a concern in any field, but as you note, when clinical practice is at stake, it can be particularly worrisome. Do you think your findings raise any potential concerns about patient safety?
Researchers are retracting a 2016 PNASpaper that described a way to create gasoline-like fuels directly from carbon dioxide in the atmosphere.
Senior author Frederick MacDonnell, a professor at the University of Texas at Arlington (UTA), told us he originally thought his team had made a preliminary breakthrough that might “solve the world’s energy problems.” Instead, he said:
In March 2017, Christopher Blanford received an email from an editor at the Journal of Crystal Growth. Blanford had been named as a suggested reviewer for a manuscript, and the editor, Arnab Bhattacharya, wanted to verify that the Gmail account the authors provided was legitimate.
It was not.
Blanford—a senior lecturer in biomaterials at the University of Manchester, UK—thought it was an “amusing coincidence” that he was chosen as a fake reviewer, given that he has written about malpractice in academic publishing. He confirmed the Gmail account was not his, and the other two suggested reviewers told Bhattacharya, a professor at the Tata Institute of Fundamental Research in Mumbai, India, the same thing.
A consultant has admitted to plagiarizing a U.S. Air Force officer in a paper on leadership, and says his company is now in jeopardy of losing top clients, including Fortune 100 companies.
Here’s a rather odd case: A postdoctoral researcher says his former boss changed his name on a paper without his permission. According to the postdoc, Antonio Herrera-Merchan, his principal investigator at University of Granada insisted on the name change to distance them both from a scandal in Herrera-Merchan’s previous lab.
After publishing a paper in Oncotarget in October 2017, Herrera-Merchan’s name was changed on the paper. Now, two versions of the paper exist: an earlier version that lists Antonio Herrera-Merchan as first author, and the current version that spells his name without “Merchan.”*
We’ve obtained an email exchange between his former boss, Pedro Medina, and Oncotarget, requesting the name change.